Immunotherapy: MAPK‐Targeted Drug Delivered by a pH‐Sensitive MSNP Nanocarrier Synergizes with PD‐1 Blockade in Melanoma without T‐Cell Suppression (Adv. Funct. Mater. 12/2019)

In article number 1806916, Haiyuan Zhang, Hubing Shi, and co-workers provide a novel framework for combining targeted therapy and immune checkpoint blockade by using a mesoporous silica nanoparticle (MSNP) system. The MSNP-carried MEK inhibitor is specifically enriched in the tumor microenvironment, and selectively internalized by tumor cells rather than T-cells. The cellular-specific delivery avoids T-cell toxicity and synergizes oncogene-targeted therapy and PD-1 blockade.